Recent Quotes
My Watchlist
Indicators
Investor Uprising 25
Markets:
Overview
News
Currencies
International
Treasuries

Kyverna Therapeutics, Inc. - Common Stock (NQ:KYTX)

7.120 -0.490 (-6.44%)
Streaming Delayed Price Updated: 3:33 PM EDT, Oct 29, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 2,541,648
Open 8.000
Bid (Size) 7.080 (4)
Ask (Size) 7.140 (1)
Prev. Close 7.610
Today's Range 6.964 - 8.110
52wk Range 1.780 - 8.447
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Kyverna Therapeutics Announces Positive Interim Phase 2 Data from KYSA-6 Study of KYV-101 in Generalized Myasthenia Gravis at AANEM 2025
From Kyverna Therapeutics, Inc.
Via GlobeNewswire
Kyverna Therapeutics Highlights Potential of KYV-101 in Rheumatoid Arthritis with Phase 1 Data from Investigator-Initiated Trial Presented at ACR Convergence 2025
From Kyverna Therapeutics, Inc.
Via GlobeNewswire

Performance

YTD
+81.6%
+81.6%
1 Month
+19.9%
+19.9%
3 Month
+84.9%
+84.9%
6 Month
+249.0%
+249.0%
1 Year
+33.8%
+33.8%

More News

Read More
Kyverna Therapeutics to Host Conference Call on Interim Phase 2 Data from KYSA-6 Study of KYV-101 in Generalized Myasthenia Gravis
From Kyverna Therapeutics, Inc.
Via GlobeNewswire
Top movers in Wednesday's session
Via Chartmill
KYVERNA INVESTIGATION ALERT: Bragar Eagel & Squire, P.C. Continues Investigation Into Kyverna Therapeutics, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
Kyverna Therapeutics Highlights Potential of KYV-101 in Multiple Sclerosis with Data from Phase 1 Investigator-Initiated Trials to be Presented at ECTRIMS
From Kyverna Therapeutics, Inc.
Via GlobeNewswire
Kyverna Therapeutics to Highlight Interim Phase 2 Data from KYV-101 KYSA-6 Study in Myasthenia Gravis at AANEM 2025
From Kyverna Therapeutics, Inc.
Via GlobeNewswire
Kyverna Therapeutics Highlights Neuroimmunology CAR T Franchise and Registrational Phase 3 Trial Design in Myasthenia Gravis at Virtual KOL Event
From Kyverna Therapeutics, Inc.
Via GlobeNewswire
Kyverna Therapeutics to Present at Upcoming Investor Conferences in September
From Kyverna Therapeutics, Inc.
Via GlobeNewswire
Kyverna Sets Pace In Race For Autoimmune CAR-T Approval By 2026
Via Benzinga
Kyverna Therapeutics Provides Business Update and Reports Second Quarter 2025 Financial Results
From Kyverna Therapeutics, Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Tuesday's Intraday Session
Via Benzinga
KYVERNA ALERT: Bragar Eagel & Squire, P.C. is Investigating Kyverna Therapeutics, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
12 Health Care Stocks Moving In Wednesday's After-Market Session
Via Benzinga
With Trials In Motion, Cash To 2027, Can Kyverna's Next Data Drop Turn The Stock Around?
Via Benzinga
This Commercial Metals Analyst Turns Bullish; Here Are Top 5 Upgrades For Tuesday
Via Benzinga
KYVERNA ALERT: Bragar Eagel & Squire, P.C. is Investigating Kyverna Therapeutics, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
Notice to Long-Term Shareholders of Kyverna Therapeutics, Inc. (NASDAQ: KYTX); Methode Electronics, Inc. (NYSE: MEI); ModivCare, Inc. (NASDAQ: MODV); and Monolithic Power Systems, Inc. (NASDAQ: MPWR) - Grabar Law Office Is Investigating Claims on Your
From Grabar Law Office
Via GlobeNewswire
ALERT: Grabar Law Office Investigates Claims for Long-Term Shareholders of Holley Inc. (NYSE: HLLY); Integra Lifesciences Holdings Corporation (NASDAQ: IART); Kyverna Therapeutics, Inc. (NASDAQ: KYTX); and Virtu Financial, Inc. (NASDAQ: VIRT)
From Grabar Law Office
Via GlobeNewswire
Notice to Long-Term Shareholders of Akero Therapeutics, Inc. (Nasdaq: AKRO); Driven Brands Holdings, Inc. (Nasdaq: DRVN); Integra Lifesciences Holdings Corporation (Nasdaq: IART); and Kyverna Therapeutics, Inc. (Nasdaq: KYTX): Grabar Law Office is
From Grabar Law Office
Via GlobeNewswire
Notice to Long-Term Shareholders of Driven Brands Holdings, Inc. (NASDAQ: DRVN); Kyverna Therapeutics, Inc. (NASDAQ: KYTX); Mercury Systems, Inc. (NASDAQ: MRCY); and Rocket Lab USA, Inc. (NASDAQ: RKLB): Grabar Law Office is Investigating Claims on Your
From Grabar Law Office
Via GlobeNewswire
Notice to Long-Term Shareholders of Archer-Daniels-Midland Co. (NYSE: ADM); Driven Brands Holdings, Inc. (Nasdaq: DRVN); Kyverna Therapeutics, Inc. (Nasdaq: KYTX); and Mercury Systems, Inc. (Nasdaq: MRCY): Grabar Law Office is Investigating Claims on Your
From Grabar Law Office
Via GlobeNewswire
Top movers in Monday's after hours session
Via Chartmill
12 Health Care Stocks Moving In Monday's After-Market Session
Via Benzinga
Notice to Long-Term Shareholders of Fluence Energy, Inc. (NASDAQ: FLNC); Kyverna Therapuetics, Inc. (NASDAQ: KYTX); Mercury Systems, Inc. (NASDAQ: MRCY); and Sage Therapeutics, Inc. (NASDAQ: SAGE): Grabar Law Office Is Investigating Claims on Your Behalf
From Grabar Law Office
Via GlobeNewswire

Frequently Asked Questions

Is Kyverna Therapeutics, Inc. - Common Stock publicly traded?
Yes, Kyverna Therapeutics, Inc. - Common Stock is publicly traded.
What exchange does Kyverna Therapeutics, Inc. - Common Stock trade on?
Kyverna Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Kyverna Therapeutics, Inc. - Common Stock?
The ticker symbol for Kyverna Therapeutics, Inc. - Common Stock is KYTX on the Nasdaq Stock Market
What is the current price of Kyverna Therapeutics, Inc. - Common Stock?
The current price of Kyverna Therapeutics, Inc. - Common Stock is 7.120
When was Kyverna Therapeutics, Inc. - Common Stock last traded?
The last trade of Kyverna Therapeutics, Inc. - Common Stock was at 10/29/25 03:33 PM ET
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.